Press Release – updated: Jul 13, 2018 12:05 EDT
EXTON, Pa., July 13, 2018 – Frontage Laboratories, Inc. has been named as a 2018 CRO Leadership Awards recipient by Life Science Leader magazine. The publication annually asks pharmaceutical and biopharmaceutical companies to rate the capability and performance of contract research organizations.
This year, Frontage was recognized in the following categories: Outstanding Capabilities – Overall and Small Pharma; Compatibility – Overall, Big Pharma and Small Pharma; Expertise – Small Pharma; Quality – Overall, Big Pharma and Small Pharma, and Reliability – Overall, Big Pharma and Small Pharma.
“We are honored to be recognized again this year as a leading contract research organization,” said Dr. Song Li Frontage CEO. “Employees at Frontage are dedicated to client satisfaction through our exceptional quality standards, professional scientific expertise, stringent regulatory compliance, and timely communications and project delivery. I would like to thank our clients for recognizing our efforts.”
Developed in 2012, the CRO Leadership Awards looks at 20+ different performance metrics, as rated by decision-making executives recruited from pharma and biopharmaceutical companies of all sizes. Screened for decision-making influence related to their work with the CROs being evaluated, sponsors provide ratings of CROs based on recent outsourced projects.
“The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive,” said Ed Miseta, Executive Editor, Life Science Leader. “Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of biopharmaceutical companies and their patients.”
Frontage is a CRO providing integrated, scientifically-driven research, analytical and development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals. We provide integrated, scientifically-driven research, analytical and development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals.
We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients.
We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance. We successfully assist clients to advance hundreds of molecules through development to commercial launch in global markets.
Source: Frontage Labs